OR WAIT null SECS
August 11, 2022
IBI324 is a potential first-in-class ophthalmic recombinant human anti-VEGF-A and anti-Ang-2 bispecific antibody.
August 09, 2022
Proper screenings, treatment, management needed for this increasingly prevalent disease.
August 03, 2022
Ranibizumab-eqrn will offer greater treatment access and choice for patients, payors, and providers in the US.
July 15, 2022
Advancements enable better diagnosis, treatment of patients.
July 14, 2022
A decade after the conclusion of the NIH-funded AREDS2 study, researchers found that the AREDS2 formula also reduces the risk of lung cancer.
June 02, 2022
All data were collected in the Fight Retinal Blindness! Registry.
June 01, 2022
This is the second FDA-approved indication for BEOVU; it was initially approved in 2019 for the treatment of wet AMD.
May 12, 2022
A look at the latest developments in retinal disease, including clinical trials and advanced therapies.
May 10, 2022
Oxurion NV finds insufficient evidence of efficacy on key clinical endpoints for THR-687 in Part A of the INTEGRAL phase 2 trial; focus will now turn to an alternative candidate and trial.
April 25, 2022
Investigators report a correlation between the risk of 5-letter visual acuity (VA) loss at 24 months for eyes with clinically significant diabetic macular edema (CSDME) and good VA initially treated and eyes that were initially observed in routine clinical practice.
Report: ortho-K expected to surge over next 2 years
Impact of vision impairment on children’s mental health
First patient dosed in phase 1 study of IBI324 for DME
Study: Neurolenses significantly impact reading speed
